308 related articles for article (PubMed ID: 38359791)
1. Harnessing human genetics and stem cells for precision cardiovascular medicine.
Caudal A; Snyder MP; Wu JC
Cell Genom; 2024 Feb; 4(2):100445. PubMed ID: 38359791
[TBL] [Abstract][Full Text] [Related]
2. Human-induced pluripotent stem cells as models for rare cardiovascular diseases: from evidence-based medicine to precision medicine.
Pan Z; Ebert A; Liang P
Pflugers Arch; 2021 Jul; 473(7):1151-1165. PubMed ID: 33206225
[TBL] [Abstract][Full Text] [Related]
3. Genome Editing and Induced Pluripotent Stem Cell Technologies for Personalized Study of Cardiovascular Diseases.
Chun YW; Durbin MD; Hong CC
Curr Cardiol Rep; 2018 Apr; 20(6):38. PubMed ID: 29666931
[TBL] [Abstract][Full Text] [Related]
4. Subtype-specific cardiomyocytes for precision medicine: Where are we now?
Zhao MT; Shao NY; Garg V
Stem Cells; 2020 Jul; 38(7):822-833. PubMed ID: 32232889
[TBL] [Abstract][Full Text] [Related]
5. The updated view on induced pluripotent stem cells for cardiovascular precision medicine.
Wang Y; Lei W; Yang J; Ni X; Ye L; Shen Z; Hu S
Pflugers Arch; 2021 Jul; 473(7):1137-1149. PubMed ID: 33595719
[TBL] [Abstract][Full Text] [Related]
6. Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association.
Musunuru K; Sheikh F; Gupta RM; Houser SR; Maher KO; Milan DJ; Terzic A; Wu JC;
Circ Genom Precis Med; 2018 Jan; 11(1):e000043. PubMed ID: 29874173
[TBL] [Abstract][Full Text] [Related]
7. Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.
Tzatzalos E; Abilez OJ; Shukla P; Wu JC
Adv Drug Deliv Rev; 2016 Jan; 96():234-244. PubMed ID: 26428619
[TBL] [Abstract][Full Text] [Related]
8. Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes.
Karakikes I; Ameen M; Termglinchan V; Wu JC
Circ Res; 2015 Jun; 117(1):80-8. PubMed ID: 26089365
[TBL] [Abstract][Full Text] [Related]
9. Induced pluripotent stem cell technology: Toward the future of cardiac arrhythmias.
Gnecchi M; Stefanello M; Mura M
Int J Cardiol; 2017 Jun; 237():49-52. PubMed ID: 28408106
[TBL] [Abstract][Full Text] [Related]
10. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
[TBL] [Abstract][Full Text] [Related]
11. Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine.
Sayed N; Liu C; Wu JC
J Am Coll Cardiol; 2016 May; 67(18):2161-2176. PubMed ID: 27151349
[TBL] [Abstract][Full Text] [Related]
12. Novel insights into disease modeling using induced pluripotent stem cells.
Egashira T; Yuasa S; Fukuda K
Biol Pharm Bull; 2013; 36(2):182-8. PubMed ID: 23370349
[TBL] [Abstract][Full Text] [Related]
13. A comment on pluripotent stem cells in next-generation biomedical theranostics.
Rossbach M
Curr Mol Med; 2013 Jun; 13(5):879-83. PubMed ID: 23642068
[TBL] [Abstract][Full Text] [Related]
14. Human-induced pluripotent stem cells in cardiovascular research: current approaches in cardiac differentiation, maturation strategies, and scalable production.
Thomas D; Cunningham NJ; Shenoy S; Wu JC
Cardiovasc Res; 2022 Jan; 118(1):20-36. PubMed ID: 33757124
[TBL] [Abstract][Full Text] [Related]
15. Deconvoluting the Cells of the Human Heart with iPSC Technology: Cell Types, Protocols, and Uses.
Yu B; Zhao SR; Yan CD; Zhang M; Wu JC
Curr Cardiol Rep; 2022 May; 24(5):487-496. PubMed ID: 35244869
[TBL] [Abstract][Full Text] [Related]
16. Concise Review: Induced Pluripotent Stem Cell Research in the Era of Precision Medicine.
Hamazaki T; El Rouby N; Fredette NC; Santostefano KE; Terada N
Stem Cells; 2017 Mar; 35(3):545-550. PubMed ID: 28100040
[TBL] [Abstract][Full Text] [Related]
17. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
[TBL] [Abstract][Full Text] [Related]
18. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y; Deng W
Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
[TBL] [Abstract][Full Text] [Related]
19. Induced pluripotent stem cell technology: a decade of progress.
Shi Y; Inoue H; Wu JC; Yamanaka S
Nat Rev Drug Discov; 2017 Feb; 16(2):115-130. PubMed ID: 27980341
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of KCNJ2 enhances maturation of human-induced pluripotent stem cell-derived cardiomyocytes.
Zhou J; Cui B; Wang X; Wang H; Zheng J; Guo F; Sun Y; Fan H; Shen J; Su J; Wang J; Zhao H; Tang Y; Gong T; Sun N; Liang P
Stem Cell Res Ther; 2023 Apr; 14(1):92. PubMed ID: 37061738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
